non tuberculous mycobacteria
Conditions
Interventions
None listed
Sponsors
Universitair Medisch Centrum Sint Radboud
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients: •Currently treated for NTM infection or recently diagnosed with NTM infection starting treatment at ULC Dekkerswald, Groesbeek, or Centre for Revalidation Beatrixoord, Haren, the Netherlands. •Diagnosis and treatment according to ATS criteria for NTM infections. Patients with pulmonary (eventually with extrapulmonary localizations) NTM infections are eligible. •Treated with at least rifampicin and ethambutol and optionally with claritromycin or azitromycin on a daily basis. •Age >=18 years. •Patient has been using drugs for at least two weeks when steady state concentrations of rifampicin and azithromycin is expected. •Informed consent has been signed.
Exclusion criteria
Exclusion criteria: •The medical state of the patients does not allow inclusion according to the physician in attendance. •The patients* clinical parameters urge immediate cessation of drugs. •The patient is pregnant. •Significant hepatic or renal dysfunction •Patients with cystic fibrosis, since these show deviating pharmacokinetics for many drugs. •Patients with HIV infection
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pharmacokinetic parameters of antimycobacterial drugs in NTM treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Determinants of pharmacokinetic parameters 2. Assessment of MIC values and pharmacodynamic parameters for response. 3. Association of pharmacokinetic and pharmacodynamic parameters with treatment outcome and toxicity. | — |
Countries
Netherlands
Outcome results
None listed